Evidence map›Paper›PMID 37640544›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2023

Immunotherapy-Responsive Neuropathic Pain and Allodynia in a Patient With Glycine Receptor Autoantibodies: A Case Report.

Babak Soleimani, Callum Board, Tony Yu, Irene Tracey, Sarosh R Irani, Peter Foley

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Recent advances in autoantibody-mediated pain.Current opinion in supportive and palliative care · 2026
    Review
  3. Article
  4. Ten Years ofNeurology(R) neuroimmunology & neuroinflammation · 2025
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Babak SoleimaniFrom the Department of Neurology (B.S.), Oxford University Hospitals; Department of Clinical Neurology (C.B.), John Radcliffe Hospital Oxford; Oxford Autoimmune Neurology Group (C.B., S.R.I.), Nuffield Department of Clinical Neurosciences University of Oxford; Department of Clinical Neurosciences (T.Y.), Royal Infirmary Edinburgh; Wellcome Centre for Integrative Neuroimaging (I.T.), University of Oxford; Department of Clinical Neurosciences (P.F.), Royal Infirmary of Edinburgh; and Anne Rowling Regenerative Neurology Clinic (P.F.), University of Edinburgh.ORCID 0000-0002-8630-4595
Callum BoardFrom the Department of Neurology (B.S.), Oxford University Hospitals; Department of Clinical Neurology (C.B.), John Radcliffe Hospital Oxford; Oxford Autoimmune Neurology Group (C.B., S.R.I.), Nuffield Department of Clinical Neurosciences University of Oxford; Department of Clinical Neurosciences (T.Y.), Royal Infirmary Edinburgh; Wellcome Centre for Integrative Neuroimaging (I.T.), University of Oxford; Department of Clinical Neurosciences (P.F.), Royal Infirmary of Edinburgh; and Anne Rowling Regenerative Neurology Clinic (P.F.), University of Edinburgh.
Tony YuFrom the Department of Neurology (B.S.), Oxford University Hospitals; Department of Clinical Neurology (C.B.), John Radcliffe Hospital Oxford; Oxford Autoimmune Neurology Group (C.B., S.R.I.), Nuffield Department of Clinical Neurosciences University of Oxford; Department of Clinical Neurosciences (T.Y.), Royal Infirmary Edinburgh; Wellcome Centre for Integrative Neuroimaging (I.T.), University of Oxford; Department of Clinical Neurosciences (P.F.), Royal Infirmary of Edinburgh; and Anne Rowling Regenerative Neurology Clinic (P.F.), University of Edinburgh.ORCID 0009-0006-2081-1363
Irene TraceyFrom the Department of Neurology (B.S.), Oxford University Hospitals; Department of Clinical Neurology (C.B.), John Radcliffe Hospital Oxford; Oxford Autoimmune Neurology Group (C.B., S.R.I.), Nuffield Department of Clinical Neurosciences University of Oxford; Department of Clinical Neurosciences (T.Y.), Royal Infirmary Edinburgh; Wellcome Centre for Integrative Neuroimaging (I.T.), University of Oxford; Department of Clinical Neurosciences (P.F.), Royal Infirmary of Edinburgh; and Anne Rowling Regenerative Neurology Clinic (P.F.), University of Edinburgh.ORCID 0000-0003-4134-6115
Sarosh R IraniFrom the Department of Neurology (B.S.), Oxford University Hospitals; Department of Clinical Neurology (C.B.), John Radcliffe Hospital Oxford; Oxford Autoimmune Neurology Group (C.B., S.R.I.), Nuffield Department of Clinical Neurosciences University of Oxford; Department of Clinical Neurosciences (T.Y.), Royal Infirmary Edinburgh; Wellcome Centre for Integrative Neuroimaging (I.T.), University of Oxford; Department of Clinical Neurosciences (P.F.), Royal Infirmary of Edinburgh; and Anne Rowling Regenerative Neurology Clinic (P.F.), University of Edinburgh.ORCID 0000-0002-7667-9748
Peter FoleyFrom the Department of Neurology (B.S.), Oxford University Hospitals; Department of Clinical Neurology (C.B.), John Radcliffe Hospital Oxford; Oxford Autoimmune Neurology Group (C.B., S.R.I.), Nuffield Department of Clinical Neurosciences University of Oxford; Department of Clinical Neurosciences (T.Y.), Royal Infirmary Edinburgh; Wellcome Centre for Integrative Neuroimaging (I.T.), University of Oxford; Department of Clinical Neurosciences (P.F.), Royal Infirmary of Edinburgh; and Anne Rowling Regenerative Neurology Clinic (P.F.), University of Edinburgh. peter.foley@nhslothian.scot.nhs.uk.ORCID 0000-0001-7039-2976
John Radcliffe Hospital · GB

Funding

Department of HealthMedical Research Council MR/V007173/1Wellcome Trust 104079/Z/14/Z
6 · The paper itself

Abstract

objectivesNeuropathic pain is common and distressing. Improved mechanistic understanding and pharmacotherapies are urgently needed. Molecularly specific pain syndromes may provide insights with translational relevance. Glycine receptors are known to play a key role in inhibitory neurotransmission in the spinal dorsal horn and have therefore been considered as targets for analgesic development. While autoantibodies directed against glycine receptors may rarely arise spontaneously in humans, a detailed phenotype of neuropathic pain and allodynia in association with these autoantibodies has not been described.

methodsWe describe the case of a previously well adult presenting with severe neuropathic pain and allodynia as part of an autoimmune brainstem and spinal syndrome with glycine receptor autoantibodies.

resultsOur patient experienced a severe illness, including marked neuropathic pain and allodynia, hypoventilation, tetraparesis, and ophthalmoplegia. A diagnosis of progressive encephalomyelitis with rigidity and myoclonus was made. Neuropathic pain was characterized with validated instruments and responded promptly to cause-directed immunotherapy. DISCUSSION: A detailed longitudinal phenotyping, using validated pain measurement instruments, of severe neuropathic pain and allodynia associated with likely pathogenic glycine receptor autoantibodies is reported. This case may have relevance for translational development of analgesics targeting glycinergic neurotransmission.

Indexed as

NeuralgiaReceptors, GlycineAdultAutoantibodiesHumansHyperalgesiaImmunotherapyAutoantibodiesReceptors, Glycine

Identifiers

PMID37640544
PMCPMC10462052
OpenAlexW4386213547

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.